Amgen issued a statement clarifying that it found no link between its experimental weight-loss drug, MariTide, and changes in bone mineral density. This announcement came a day after data from an early-stage study prompted a 7% decline in the company's stock due to analyst concerns.
The company stated, 'The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide.' This direct rebuttal aims to reassure investors and the medical community regarding the safety profile of its highly anticipated obesity treatment.
Amgen reiterated its confidence in MariTide's potential and confirmed that it looks forward to sharing further data from its mid-stage study later this year. Addressing these safety questions is critical for the drug's continued development and its competitive positioning in the burgeoning obesity market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.